Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto*, Artur Oreziak, Roberto Barriales-Villa, Theodore P. Abraham, Ahmad Masri, Pablo Garcia-Pavia, Sara Saberi, Neal K. Lakdawala, Matthew T. Wheeler, Anjali Owens, Milos Kubanek, Wojciech Wojakowski, Morten K. Jensen, Juan Gimeno-Blanes, Kia Afshar, Jonathan Myers, Sheila M. Hegde, Scott D. Solomon, Amy J. Sehnert, David ZhangWanying Li, Mondira Bhattacharya, Jay M. Edelberg, Cynthia Burstein Waldman, Steven J. Lester, Andrew Wang, Carolyn Y. Ho, Daniel Jacoby, EXPLORER-HCM study investigators, Hans peter Brunner-La Rocca

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)759-769
Number of pages11
JournalLancet
Volume396
Issue number10253
DOIs
Publication statusPublished - 12 Sep 2020

Keywords

  • NATRIURETIC PEPTIDE
  • TASK-FORCE
  • OUTCOMES
  • DIAGNOSIS
  • MANAGEMENT
  • EXERCISE

Cite this